Heron Therapeutics is trading 23.82% down now at $0.37 after its August 10, 2026, second-quarter results missed revenue and earnings expectations.
- Revenue was $37.7 million versus the $42.19 million consensus estimate; management withdrew full-year 2026 guidance and paused planned second-half sales-force expansion.
- The company cited uncertainty around generic competition following the adverse CINVANTI patent ruling and is exploring strategic alternatives.
- Heron confirmed the scheduled earnings release and conference call.